 State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S. CAMBRIDGE, Mass. and ROSTOCK, Germany, Feb. 12, 2020 GLOBE NEWSWIRE -- CENTOGENE CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists CAP. The CAPs Biorepository Accreditation Program is designed to improve the quality and consistency of biorepositories through requirements for standardization that will result in high-quality human specimens and genetic materials that can be used to support research. 